Home
Your Profile
Become a Member/Get Newsletter
Contact Us
Recent Updates
Current Papers
Search All Papers
Search Comments
Research News
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Tech Corner
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by
NARSAD
, the Brain and Behavior Research Fund, and was created with funding from the
U.S. National Institute of Mental Health
.
Printable version
SZGene - Gene overview of all published SZ-association studies for DRD3
Gene:
DRD3
(D3DR; ETM1; FET1)
View on AlzGene
View on PDGene
Protein:
dopamine receptor D3
(essential tremor 1)
Chromosome:
3
(View:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
X
Y
MT
)
Status:
Updated 21 October 2010
1. Case-Control Studies (by ethnic group)
SZ Cases
Normal Controls
Study
Population
Source
# Polys
# Subjects
(% women)
DX
Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
Comment
Caucasian
Anney, 2002
UK, Ireland
CL
7
(detail)
368
(28%)
IV
-
46 + 13
(-)
368
(28%)
43 + 12
(-)
Negative
Asherson, 1996
UK (III)
CL
1
(detail)
100
(22%)
M
-
-
100
(36%)
-
Positive
Asherson, 1996
UK (I)
CL
1
(detail)
72
(31%)
M
-
-
100
(36%)
-
Positive
Asherson, 1996
UK (II)
CL
1
(detail)
81
(27%)
M
-
-
100
(36%)
-
Positive
Baritaki, 2004
Greece
CL
1
(detail)
114
(41%)
IV
25.5 + 9.2
(14-60)
50.6 + 13.3
(-)
192
(39%)
45.1 + 8.7
(-)
Negative
Barlas, 2008
Turkey
CL
1
(detail)
92
(17%)
IV
-
30.4 + 10.5
(-)
100
(19%)
31.7 + 9.2
(-)
Negative
Betcheva, 2009
Bulgaria
CL
8
(detail)
185
(-)
IV
-
-
184
(-)
-
Negative
Costas, 2008
Spain
CL
7
(detail)
273
(-)
IV
-
39.9 + 10.8
(18-60)
512
(-)
38.8 + 11.1
(18-60)
Trend
Crocq, 1992
UK
CL
1
(detail)
68
(37%)
IIIR
-
43.1 + 13.7
(19-72)
68
(43%)
45.9 + 14.9
(20-83)
Positive
Crocq, 1992
France
CL
1
(detail)
73
(27%)
IIIR
-
38.4 + 12
(20-69)
71
(41%)
33.9 + 8.9
(20-65)
Positive
Di Bella, 1994
Italy
CL
1
(detail)
85
(45%)
IIIR
21.8 + 5
(-)
33.6 + 11.3
(-)
78
(64%)
29 + 6.6
(-)
Negative
Dollfus, 1996
France
PO
1
(detail)
62
(-)
M
-
-
161
(-)
-
Negative
Domingeuz, 2006
Spain
CL
17
(detail)
260
(35%)
IV
-
-
354
(55%)
-
Trend
Durany, 1996
Spain
CL
1
(detail)
107
(58%)
10
-
55 + 16
(-)
100
(59%)
53 + 21
(-)
Negative
Ebstein, 1997
Italy
CL
1
(detail)
80
(24%)
IIIR
20.8 + 4.6
(13-34)
31.2 + 9.5
(14-64)
63
(51%)
36.5 + 10.6
(27-69)
Positive
Ebstein, 1997
Israel
CL
1
(detail)
87
(37%)
IIIR
20.9 + 4.9
(13-34)
39.3 + 11.3
(19-71)
136
(49%)
32.9 + 11.5
(18-80)
Positive
Fathalli, 2007
Canada (Montreal)
CL
1
(detail)
194
(28%)
M
-
-
89
(60%)
-
Negative
Fathalli, 2007
Canada (Ottawa)
CL
1
(detail)
50
(14%)
M
-
-
29
(45%)
-
Negative
Fathalli, 2007
Tunisia, Hungary
CL
1
(detail)
164
(29%)
M
-
-
54
(24%)
-
Negative
Gaitonde, 1996
UK
CL
1
(detail)
84
(45%)
U
23.5 + 6.4
(16-49)
44.3 + 14.8
(-)
77
(48%)
41.7 + 19
(-)
Negative
Gourion, 2005
France
CL
1
(detail)
210
(32%)
IV
21.6 + 4.8
(-)
31.4 + 8.5
(-)
99
(54%)
30.5 + 9.9
(-)
Negative
Griffon, 1996
France
CL
1
(detail)
119
(-)
IIIR
-
-
85
(-)
-
Positive
Griffon, 1996
Overlaps with
Crocq, 1992 (France)
CL
1
(detail)
119
(-)
IIIR
-
-
85
(-)
-
n.a.
Hawi, 1998
Ireland
CL
1
(detail)
198
(32%)
IIIR
-
-
235
(44%)
-
Negative
Jonsson, 1993
Overlaps with
Jonsson, 2003
CL
1
(detail)
76
(32%)
IIIR
-
47
(20-90)
53
(38%)
39
(29-55)
n.a.
Jonsson, 1999
Sweden
CL
2
(detail)
110
(35%)
IIIR
-
45.5
(20-90)
83
(41%)
38.1
(26-56)
Trend
Jonsson, 2003
Sweden
CL
1
(detail)
156
(39%)
IIIR
-
42.7 + 16.9
(-)
442
(44%)
40.9 + 12.3
(-)
Negative
Jonsson, 2004
Germany
CL
1
(detail)
649
(46%)
IV
-
38.7 + 12.2
(-)
584
(20%)
30.2 + 7.6
(-)
Negative
Joober, 2000
Overlaps with
Fathalli, 2007
CL
1
(detail)
106
(29%)
IV
-
39.5 + 8.3
(-)
89
(-)
-
n.a.
Kennedy, 1995
Italy
CL
1
(detail)
97
(-)
IIIR
-
-
64
(-)
-
Trend
Krebs, 1998
Overlaps with
Gourion, 2005
CL
1
(detail)
89
(38%)
IIIR
-
33.3 + 9.2
(-)
52
(50%)
35.4 + 10
(-)
n.a.
Lafuente, 2008
Spain
CL
1
(detail)
243
(46%)
IV
-
34 + 13
(-)
291
(62%)
61.7 + 11
(-)
Negative
Laurent, 1994
France
CL
1
(detail)
76
(28%)
IIIR
-
42 + 12.3
(-)
86
(42%)
48 + 8.3
(-)
Negative
Lorenzo, 2006
Spain
CL
1
(detail)
178
(-)
IV
-
-
132
(-)
-
Negative
Mant, 1994
UK
CL
1
(detail)
66
(42%)
IIIR
-
46.6 + 16.8
(-)
97
(44%)
46.6 + 19.8
(-)
Positive
Mas, 2009
Overlaps with
Lafuente, 2008
CL
12
(detail)
159
(-)
IV
-
-
373
(54%)
51.9 + 19
(-)
Negative
Maziade, 1997
Canada
CL
1
(detail)
70
(26%)
IIIR
19.6 + 4.6
(-)
-
79
(-)
44.2 + 13.6
(-)
Positive
Meszaros, 2000
Austria
CL
1
(detail)
72
(39%)
IIIR
-
30.5 + 11.8
(-)
120
(63%)
33.6 + 8.1
(-)
Negative
Nimgaonkar, 1993
Overlaps with
Nimgaonkar, 1996 (Pittsburgh I)
CL
1
(detail)
53
(38%)
IIIR
-
37.8 + 11.4
(-)
61
(52%)
30.5 + 9.5
(-)
n.a.
Nimgaonkar, 1996
USA (Pittsburgh I)
CL
1
(detail)
65
(40%)
IIIR
-
37.2 + 10.8
(-)
165
(-)
-
Trend
Nimgaonkar, 1996
USA (Houston)
CL
1
(detail)
50
(72%)
IIIR
-
37.2 + 9.9
(-)
51
(-)
-
Negative
Nothen, 1993a
Overlaps with
Rietschel, 1996
CL
1
(detail)
111
(-)
U
-
-
100
(-)
-
n.a.
Nothen, 1993b
Overlaps with
Nothen, 1993a
CL
1
(detail)
60
(33%)
IIIR
25.2 + 8
(14-46)
34.8 + 11
(-)
60
(47%)
28.2 + 5.2
(-)
n.a.
Nothen, 1993b
Germany
CL
1
(detail)
60
(33%)
IIIR
25.2 + 8
(14-46)
34.8 + 11
(-)
60
(47%)
28.2 + 5.2
(-)
Negative
Rietschel, 1996
Germany
CL
1
(detail)
146
(40%)
IIIR
-
32.6 + 10.1
(-)
100
(49%)
30.2 + 9.3
(-)
Negative
Rybakowski, 2001
Poland
CL
1
(detail)
119
(38%)
M
-
30
(18-63)
85
(53%)
27
(22-60)
Negative
Sabate, 1994
France
PO
2
(detail)
50
(-)
IIIR
-
-
50
(-)
-
Negative
Saiz, 2009
Spain
CL
1
(detail)
288
(40%)
IV
-
36.3 + 12.4
(-)
421
(49%)
40.6 + 11.3
(-)
Positive
Segman, 1999
Israel
CL
1
(detail)
137
(39%)
IV
-
50.7 + 11.1
(-)
117
(53%)
44 + 9.4
(-)
Positive
Segman, 2000
Overlaps with
Segman, 1999
CL
1
(detail)
115
(48%)
IV
-
-
97
(53%)
-
n.a.
Shaikh, 1996
UK
CL
1
(detail)
133
(-)
IIIR
-
-
109
(-)
-
Positive
Sivagnanasundaram, 2000
Overlaps with
Gaitonde, 1996
CL
1
(detail)
73
(-)
IIIR
-
-
56
(-)
-
n.a.
Sivagnanasundaram, 2000
UK
CL
3
(detail)
73
(-)
IIIR
-
-
56
(-)
-
Positive
Spurlock, 1998
UK
CL
1
(detail)
31
(-)
IIIR
-
-
31
(-)
-
Positive
Spurlock, 1998
Sweden
CL
1
(detail)
67
(-)
IIIR
-
-
71
(-)
-
Positive
Spurlock, 1998
Portugal
CL
1
(detail)
76
(-)
IIIR
-
-
33
(-)
-
Positive
Spurlock, 1998
Ireland
CL
1
(detail)
36
(-)
IIIR
-
-
83
(-)
-
Positive
Spurlock, 1998
France
CL
1
(detail)
30
(-)
IIIR
-
-
31
(-)
-
Positive
Spurlock, 1998
Austria
CL
1
(detail)
71
(-)
IIIR
-
-
57
(-)
-
Positive
Staddon, 2005
Spain
CL
3
(detail)
118
(36%)
IV
23.7 + 8
(-)
40.6 + 14.4
(-)
162
(50%)
-
Positive
Szekeres, 2004
Hungary
CL
1
(detail)
75
(55%)
IV
-
-
45
(62%)
36.4 + 12.8
(-)
Negative
Talkowski, 2006
Overlaps with
Talkowski, 2008
CL
13
(detail)
331
(-)
IV
-
-
274
(55%)
-
Positive
Talkowski, 2008
USA
CL
18
(detail)
478
(-)
IV
-
-
501
(-)
-
Positive
Ventriglia, 2002
Italy
CL
1
(detail)
114
(-)
IV
-
-
138
(-)
-
Positive
Virgos, 2001
Spain
CL
1
(detail)
262
(40%)
9
-
61.4
(19-90)
278
(39%)
54.2
(21-90)
Negative
Zai, 2010
Canada
CL
15
(detail)
167
(37%)
IV
-
37.5 + 10.8
(-)
167
(37%)
-
Negative
African Descent
Nimgaonkar, 1996
USA (Pittsburgh II)
CL
1
(detail)
65
(55%)
IIIR
-
37.2 + 9.9
(-)
123
(-)
-
Negative
Asian
Chen, 1997
Taiwan
CL
1
(detail)
178
(46%)
IIIR
-
47
(-)
100
(53%)
45
(-)
Negative
Fujiwara, 1997
Japan
CL
1
(detail)
52
(-)
M
-
-
36
(-)
-
Negative
Inada, 1995
Japan
CL
1
(detail)
113
(52%)
U
-
50
(22-86)
48
(50%)
54
(20-80)
Negative
Ishiguro, 2000
Japan (II)
CL
1
(detail)
99
(47%)
M
-
47.8 + 9.8
(-)
132
(45%)
48.5 + 11.3
(-)
Positive
Ishiguro, 2000
Japan (I)
CL
4
(detail)
153
(42%)
M
-
45.3 + 12.1
(-)
122
(52%)
47.2 + 10.5
(-)
Positive
Iwata, 2003
Japan
CL
2
(detail)
51
(57%)
IV
13.5 + 1.7
(9-16)
20 + 7
(-)
148
(56%)
21 + 7
(-)
Negative
Ma, 2008
China
CL
1
(detail)
329
(38%)
IV
-
47 + 11.3
(-)
288
(45%)
35 + 8.1
(-)
Negative
Morimoto, 2002
Japan
CL
1
(detail)
48
(-)
10
-
-
48
(-)
-
Positive
Nanko, 1993
Japan
CL
1
(detail)
91
(45%)
IIIR
-
35.7 + 10.7
(19-63)
90
(48%)
27.8 + 6.4
(19-54)
Negative
Nunokawa, 2009
Japan (I)
CL
16
(detail)
595
(47%)
IV
-
40.2 + 14.1
(-)
598
(48%)
38.1 + 10.5
(-)
Negative
Nunokawa, 2009
Japan (II)
CL
4
(detail)
2126
(47%)
IV
-
47.3 + 14.3
(-)
2228
(47%)
46.6 + 13.9
(-)
Negative
Ohara, 1996
Japan
CL
1
(detail)
153
(50%)
IV
26.3 + 9.5
(-)
46.3 + 16
(-)
121
(58%)
34.4 + 14.1
(-)
Negative
Saha, 1994
Singapore
CL
1
(detail)
137
(0%)
9
-
35.6
(-)
125
(0%)
38
(-)
Negative
Tanaka, 1996
Overlaps with
Nunokawa, 2009
CL
1
(detail)
100
(48%)
IIIR
-
44.2 + 12
(15-70)
100
(29%)
42.7 + 23.7
(22-86)
n.a.
Utsunomiya, 2008
Japan
CL
1
(detail)
246
(48%)
IV
-
51.1 + 11.2
(-)
198
(47%)
55 + 6.3
(-)
Positive
Yang, 1993
China
CL
1
(detail)
107
(33%)
RDC
-
28.8 + 7.9
(15-53)
98
(36%)
25 + 6.9
(19-50)
Negative
Other/Mixed
Kennedy, 1995
USA, Canada
CL
1
(detail)
117
(-)
IIIR
-
-
188
(-)
-
Trend
Lovlie, 2001
India
CL
1
(detail)
56
(48%)
IV
-
45.5 + 16
(-)
22
(45%)
43 + 15
(-)
Negative
Semwal, 2002
India
CL
1
(detail)
536
(44%)
IV
-
22.8 + 7
(-)
936
(47%)
32.9 + 12.7
(-)
Negative
Contact us
if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
Affecteds
Unaffecteds
Study
Population
# Polys
# Families
# Subjects
(% women)
DX
Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
Comment
Caucasian
Ambrosio, 2004
Portugal
1
(detail)
90
90
(36%)
IV
-
-
180
(50%)
-
Negative
Fallin, 2005
USA
5
(detail)
263
274
(26%)
IV
19.5 + 4.5
(-)
-
548
(50%)
-
Negative
Fathalli, 2007
Overlaps with
Fathalli, 2007 (CC)
1
(detail)
183
-
M
-
-
-
-
n.a.
Kalsi, 1998
UK, Iceland
1
(detail)
23
113
(-)
IIIR
-
-
262
(-)
-
Negative
Macciardi, 1994
Italy
1
(detail)
42
42
(26%)
IIIR
-
26
(19-45)
84
(50%)
-
Negative
Talkowski, 2006
USA
13
(detail)
151
151
(-)
IV
-
-
302
(50%)
-
Positive
Talkowski, 2008
Bulgaria
18
(detail)
659
659
(50%)
IV
-
-
1318
(50%)
-
Negative
Zai, 2010
Canada, USA
15
(detail)
95
-
IV
-
-
-
-
Negative
Other/Mixed
Kremer, 2000
Palestine
1
(detail)
129
129
(32%)
IV
-
28.9 + 8.2
(16-51)
258
(50%)
-
Negative
Malhotra, 1998
USA
1
(detail)
58
58
(28%)
IIIR
-
35.5 + 7.1
(-)
116
(50%)
-
Negative
Prasad, 1999
India
1
(detail)
66
-
IV
-
-
-
-
Negative
Rothschild, 1996
USA
1
(detail)
71
-
IIIR
-
-
-
-
Negative
Talkowski, 2006
India
11
(detail)
141
141
(-)
IV
-
-
282
(50%)
-
Positive
Williams, 1998
Europe
1
(detail)
57
57
(39%)
IIIR
-
-
114
(50%)
-
Positive
Contact us
if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:
Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:
Number of polymorphisms tested per gene and per sample.
Onset Age and Age:
Mean or median age at onset or examination, respectively.
DX:
Criteria used to determine SZ diagnosis -> "IIIR"(DSM-IIIR), "IV" (DSM-IV), "9" (ICD-9), "10" (ICD-10), "M" (Mixed), "RDC" (Research Diagnostic Criteria), "U" (Unknown).
Result:
Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-)
: Either no data provided or in case of overlap, data included in original study.
SZGene Recent Updates
SZGene Stats
Studies: 1727
Genes: 1008
Polymorphisms: 8788
Meta-analyses: 287
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.
SRF News
SRF Comments
Text Size
Reset Text Size
Email this page
Research Participants
Collaborators
Copyright © 2005-2024 Schizophrenia Research Forum
Privacy Policy
Disclaimer
Disclosure
Copyright